Replimune Group Inc

NASDAQ:REPLUnited States

Replimune Group, Inc. a clinical-stage biotechnology company engaged in the development of a novel class of oncolytic immunotherapies. The Company’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. RP1 (vusolimogene oderparepvec) is its lead product candidate and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response. It is also developing additional product candidates, RP2 and RP3, to enhance anti-tumor immune responses and are intended to address additional tumor types, including traditionally less immune responsive tumor types. RP2 additionally expresses an anti-CTLA-4 antibody-like molecule, as well as GALV-GP R- and GM-CSF.

Contact Information

Headquarters

500 Unicorn Park DrWOBURN, MA, United States 01801-3377

Phone

781-222-9600

Fax

302-655-5049

Executives

Executive Chairman of the Board

Philip Astley-Sparke

Chief Executive Officer, Director

Sushil Patel

Chief Financial Officer

Emily Hill

Chief Commercial Officer

Christopher Sarchi

Chief Medical Officer

Konstantinos Xynos